HCA Healthcare, Inc. (HCA) Guidance & Earnings Results

On 2026-07-24 HCA Healthcare, Inc. mixed guidance: "FY26 revenue narrowed to $77.0-79.5B from $76.5-80.0B; FY26 net income lowered to $6.3-6.7B from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HCAHCA Healthcare, Inc.Follow HCA — free

Medical Care Facilities · Healthcare

—

Price chart with a free account

Market cap: 101.5B
P/E TTM: 15.7
Dividend yield: 0.6%
52-week: —
Next earnings: 27 Oct, in 3 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
24 Jul 26	Mixed	FY26 revenue narrowed to $77.0-79.5B from $76.5-80.0B; FY26 net income lowered to $6.3-6.7B from $6.495-7.035B · full year
14 Jul 26	Mixed	FY26 revenue narrowed to $77.0-79.5B from $76.5-80.0B; net income lowered to $6.300-6.700B from $6.495-7.035B; Adjusted EBITDA narrowed to $15.400-16.100B from $15.550-16.450B; EPS lowered to $28.70-30.50 from $29.10-31.50; capex unchanged at $5.0-5.5B; health insurance exchanges impact revised to ($1.000)-($1.200)B from ($600)-($900)M; Medicaid supplemental programs revised to $300-500M from ($50 · full year
24 Oct 25	Raised	Revenue guidance raised to $75-76.5B from $74-76B; EPS to $27-28 from $25.50-27.00 · full year
25 Jul 25	Raised	FY2025 revenue raised to $74.00-76.00B from $72.80-75.80B; net income raised to $6.11-6.48B from $5.85-6.29B; Adjusted EBITDA raised to $14.70-15.30B from $14.30-15.10B; EPS raised to $25.50-27.00 from $24.05-25.85; capex ~$5.0B (unchanged). · full year

HCA Healthcare, Inc. — questions

What guidance did HCA Healthcare, Inc. give?: On 2026-07-24: "FY26 revenue narrowed to $77.0-79.5B from $76.5-80.0B; FY26 net income lowered to $6.3-6.7B from $6.495-7.035B"
When does HCA Healthcare, Inc. report earnings?: HCA Healthcare, Inc.'s next earnings report is expected on 2026-10-27.

Every figure on this page comes from HCA Healthcare, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.